Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

1.73
CHF
+0.56
(+48.50%)
-0.75EPS
Mar 02Next Earn
Inovio Pharmaceuticals, Inc.
BX:GBM
(BX Swiss)

Recent

price

1.73

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
2.86
3.72
1.45
3.51
2.12
7.14
5.8
6.2
3.95
0.5
0.57
0.1
0.52
0.04
0.01
- -
- -
Revenue per Share
-8.19
-5.8
-6.92
-17.19
-7.33
-5.14
-12.09
-12.94
-12.57
-14.51
-12.87
-17.45
-14.07
-6.09
-3.95
-1.81
-0.89
Basic EPS, GAAP
-5.69
-7.57
-7.93
-4.05
-6.33
-2.68
-10.9
-10.79
-9.81
-12.01
-13.89
-12.47
-10.92
-5.62
-3.85
-1.9
-0.93
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
21.25
16.83
11.43
11.97
21.97
29.19
19.97
18.91
10.73
0.41
29.62
22.06
10.54
5.15
1.9
0.35
-0.31
Book Value per Share
11.52
9.92
5.57
8.36
19.03
26.86
17.04
16.72
8.84
-1.28
28.74
21.34
9.94
5.15
1.9
0.35
-0.31
Tangible Book Value per Share
2
3
3
4
5
6
6
7
8
8
13
17
20
22
27
47
80
Basic Weighted Avg Shares
6
10
4
13
10
41
35
42
30
4
7
2
10
1
- -
- -
- -
Sales/Revenue/Turnover
-312.79
-226.9
-598.36
-159.97
-377.71
-86.97
-218.38
-200.48
-308.68
-2,702.1
-1,674.25
-16,972.34
-2,607.35
-16,036.67
-51,616.91
-132,871.32
-25,953.76
Operating Margin (%)
2
2
2
2
2
2
3
3
5
6
5
5
5
4
3
3
3
Depreciation Expense
-18
-15
-20
-66
-36
-29
-74
-88
-97
-119
-166
-304
-280
-135
-107
-85
-71
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-286.65
-155.72
-477.56
-490.29
-345.44
-71.94
-208.49
-208.92
-318.12
-2,902.75
-2,245.39
-17,109.87
-2,726.67
-16,239.87
-49,254.27
-130,000
-23,798.9
Profit Margin (%)
16
21
8
30
85
140
81
103
53
62
429
383
218
111
63
17
-38
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
97
37
30
29
11
9
7
5
LT Debt
47
48
35
53
112
176
123
142
87
5
461
400
222
117
69
24
-34
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-32.9
-32.52
-48.17
-152.12
-44.14
-20.35
-49.33
-66.4
-84.57
-264.15
-71.64
-70.55
-89.97
-79.55
-115.42
-183.47
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
6
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
82
110
Market Capitalization
- -
123
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
39
40
51
Cash, Cash Equivalents & STI
38
37
48
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
38
40
89
Payables & Accruals
4
5
6
ST Debt
3
3
3
Deferred Revenue
- -
- -
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
807.35%
-42.27%
-64.82%
Free Cash Flow
40.99%
-10.55%
-14.97%
Net Income, GAAP
22.62%
-3.7%
-20.8%
Sales/Revenue/Turnover
13.89%
33.29%
-69.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.31
-1.19
-0.89
-0.6
-3.95
2025
-0.51
-0.61
-0.87
0.05
-1.81
2026
-0.28
-0.07
-0.5
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines designed to treat and protect against HPV-related diseases, cancer, and infectious diseases. Its core products include DNA plasmid-based medicines and proprietary CELLECTRA® delivery devices which facilitate intracellular delivery of these DNA medicines without chemical adjuvants or viral vectors. The company’s pipeline features candidates such as INO-3107 for recurrent respiratory papillomatosis (RRP), ongoing development of DNA medicines targeting HPV-related anal dysplasia, oropharyngeal squamous cell carcinoma (OPSCC), glioblastoma multiforme (GBM), and vaccine boosters for Ebola. Inovio operates primarily in North America, Europe, and Asia through collaborations. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio maintains strategic partnerships including a clinical collaboration and supply agreement with Coherus BioSciences for combination therapy trials and collaboration with ApolloBio for Phase 3 trials in China. In the last 1-2 years, Inovio has focused on advancing INO-3107 through the regulatory pathway, initiating device design verification testing of its CELLECTRA device to support a Biologics License Application (BLA) submission planned for late 2025, aiming for FDA acceptance by year-end and potential approval by mid-2026. The company has reported positive Phase 1/2 trial results demonstrating significant clinical benefit in reducing surgical interventions for RRP patients. Additionally, Inovio advanced proof-of-concept trials for DNA-encoded monoclonal antibodies as a next-generation platform. The company strengthened its financial position with over $60 million in net proceeds from equity offerings in 2024 and completed a $25 million public offering in mid-2025. These capital raises support ongoing clinical development and commercial readiness, including launch planning for INO-3107 and expansion of its DNA medicines platform technologies in immuno-oncology and infectious diseases. Inovio continues to pursue innovation via acquisitions such as Bioject Medical Technologies' needle-free injection assets to enhance its delivery technology portfolio. Overall, Inovio is focused on leveraging its proprietary DNA medicine technology and delivery systems to develop a novel class of therapeutics for viral infections, HPV-associated malignancies, and cancer, positioning itself for transition to a commercial-stage biotechnology company within the near future.

Company News

  • INOVIO to Participate in Upcoming Investor Conferences

  • Inovio Pharmaceuticals Q3 Earnings Call Highlights

  • Inovio Pharmaceuticals, Inc. (INO) Q3 2026 Earnings Call Transcript

  • INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights

  • INOVIO Announces Pricing of Approximately $75 Million Public Offering

  • INOVIO Announces Proposed Public Offering of its Common Stock

  • Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages

  • 4 Biotech Stocks Seeing Unusual Options Volume Today

  • INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026

  • INOVIO to Participate in Upcoming Scientific Conferences

  • Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript

  • Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

  • Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket

  • INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

  • INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

  • Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)

  • Bet on 4 Top-Ranked Stocks With Rising P/E

  • Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

  • Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

  • Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP